TALK TO A REP

Accurate &
Reliable Data

Exceptional accuracy for one year1,7.

TALK TO A REP

Most accurate CGM
in low glucose ranges‡,1,2,3,7

7.7

MAD (mg/dL).

Overall MARD of

8.8 %

with no accuracy
variability from frequent sensor changes1,7.

Essentially

no false
alerts

NO FALSE
ALERTS

because of compression4.

The

most
dependable

MOST
DEPENDABLE

predictive alerts¶,1,3.

Improved Patient Experience

Patients overwhelmingly report an improved diabetes management experience

85%

Reported improved confidence over control of their diabetes5.

86%

Reported less
day-to-day burden5.

80%

Were more motivated to keep up with diabetes managment5.

See how Eversense 365 can help your patients.

See how Eversense 365
can help your patients.

TALK TO A REP

Positive Real-World Outcomes

Late Breaking Data

Users of the Eversense 365 CGM system with open-loop insulin regimens achieved positive time in range and hypoglycemia outcomes indicating effective management of diabetes over a one-year period:

7.14%

Mean Glucose Management Indicator (GMI)6

Mean Glucose
Management
Indicator (GMI)6

66%

Mean Time in Range6

Mean Time
in Range6

>75%

Achieve Hypoglycemic targets6

Achieve
Hypoglycemic
targets6

Eversense 365 vs Traditional
Short-Term CGMs

Eversense 3651Short-Term Traditional
CGMs like Libre 3 Plus
and Dexcom G72,3
Sensor Lifetime365 days15 days
Survivability Rate at Lifetime90%68.3-80.5%
Compression LowsVirtually noneYes
Accuracy in Low Glucose
(MAD mg/dL)		7.712.5-15.5
CGM Changes Per Year124
Low Glucose Events
Detected (at 60 mg/dL)		91%76%
On-Body Vibration AlertsYesNo
Removable Smart Transmitter*YesNo
AdhesiveSilicone-basedAcrylic-based

Eversense 365 vs Traditional
Short-Term CGMs

EverSense
3651		Short-Term Traditional
CGMs like Libre 3 Plus
and Dexcom G72,3
Sensor
Lifetime		365 days15 days
Survivability
Rate at
Lifetime		90%68.3-80.5%
Compression
Lows		Virtually
none		Yes
Accuracy
in Low Glucose
(MAD mg/dL)		7.712.5-15.5
CGM
Changes
Per Year		124
Low Glucose
Events
Detected
(at 60 mg/dL)		91%76%
On-Body
Vibration
Alerts		YesNo
Removable
Smart
Transmitter*		YesNo
AdhesiveSilicone
based		Acrylic
based

Getting Started
is easy

LEARN MORE

Getting Started
is easy

LEARN MORE

Do You Have Questions?

TALK TO A REP

* There is no glucose data generated when the transmitter is removed.
‡ at <54 mg/dL Eversense 365 MAD is 7.7, G7 15 Day MAD is 12.5, and Libre 3 PLUS MAD is 15.5
¶ 91% (at 60mg/dL) Hypoglycemic events detected correctly with Eversense 365. 79% with Dexcom G7 15 Day and 76% with Libre 3 PLUS.

1. Senseonics. (2026) Eversense 365 Continuous Glucose Monitoring System User Guide. LBL-7702-01-001.
2. Abbott. (2024) Freestyle Libre 3 PLUS User Guide ART49385-001.
3. Dexcom (2025) G7 15 day User Guide AW-1000411-10 Rev 002 MT-1000411-10
4. Christiansen MP et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: Diabetes Technology & Therapeutics 2018; 20(3):197-206.
5. Barnard KD, et al. Acceptability of implantable continuous glucose monitoring sensor. Journal of Diabetes Science and Technology 2018;12(3):634-638.
6. Davis K et al. Real-World Evaluation Evaluation of the Implantable One Year Eversense 365 CGM System. Diabetes Technology and Therapeutics Vol 28;3 suppl: ATTD Barcelona 2026, page 595
7. Bailey TS, et.al., Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study. Diabetes Technology & Therapeutics, 2025 Jan 27. doi: 10.1089 / dia.2024.0592.

© 2026 Senseonics, Incorporated. All rights reserved.

20451 Seneca Meadows Parkway
Germantown, MD 20876-7005 USA
844-SENSE4U (736-7348)
eversensecgm.com

Eversense, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Other brands and their products are trademarks or registered trademarks of their respective holders and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a healthcare provider. The Eversense 365 CGM System is a prescription device; patients should talk to their healthcare provider to learn more. For safety information, see bit.ly/eversensesafety

MKT-002121 Rev 1

CLINICAL EVIDENCE

GETTING STARTED

RESOURCES

TALK TO A REP

Senseonics
Conditions of Use

Senseonics Privacy & Cookie Statement

Eversense
EULA

Eversense Privacy Policy

Eversense Legal & Warranty

Eversense
Patents

Product
Security

Senseonics Conditions of Use

Senseonics Privacy & Cookie Statement

Eversense EULA

Eversense Privacy Policy

Eversense Legal & Warranty

Eversense Patents

Product Security